Inhibitors PCSK9 - experience after two years of practice in the Czech Republic

Abstract

Treatment with monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) can further lower LDL cholesterol (low denstiy lipoprotein) by cca 50-60 %.

Keywords

• cholesterol
• drug therapy
• LDL cholesterol metabolism